Second Opinions for Breast Cancer Treatment: Factors and Effects

Share this content:
Education, genetic testing, and interest in one’s treatment are all factors influencing whether a patient seeks a second opinion for breast cancer treatment.
Education, genetic testing, and interest in one’s treatment are all factors influencing whether a patient seeks a second opinion for breast cancer treatment.

Education, genetic testing, and interest in one's treatment are all factors influencing whether a patient seeks a second opinion for breast cancer treatment, according to an article published in JAMA Oncology.1

The availability of many treatment regimens for breast cancer, as well as the ever-increasing list of genetic biomarkers for which oncologists test, can make medical decision making difficult for patients, leading to second consultations. It is unclear, however, which factors influence patients to seek a second opinion, and whether second opinions tend to influence treatment decision making.

For this survey-based study, researchers identified 3880 patients with stage I or II breast cancer identified through the Surveillance, Epidemiology, and End Results (SEER) registries of Georgia and Los Angeles County, 1901 of which were included in the sample.

Nearly 10% (168) of patients solicited a second opinion; factors associated with solicitation included being college educated, frequently using online support groups, and a preference for making one's own treatment decisions. Patients who had a variant of unknown significance (VUS) result on germline genetic tests were 3 times as likely to seek a second opinion.

RELATED: One-stage Breast Reconstruction After Mastectomy Linked With Higher Complication Risk

Second opinions did not, however, appear to increase the likelihood of chemotherapy receipt.

The authors concluded that second opinions are likely to be solicited more often as genomic panels grow more complex. The study's results indicate a need for oncologists to be better prepared to handle patient questions, particularly when genetic tests yield inconclusive results.

Reference

  1. Kurian AW, Friese CR, Bondarenko I, et al. Second opinions from medical oncologists for early-stage breast cancer: prevalence, correlates, and consequences. JAMA Oncol. 2016 Dec 29. doi: 10.1001/jamaoncol.2016.5652 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters